140 related articles for article (PubMed ID: 15171646)
1. [Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population].
Fu LQ; Huang F; Wu DZ; Guo JH
Yao Xue Xue Bao; 2004 Mar; 39(3):161-3. PubMed ID: 15171646
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism analysis of cytochrome P4502C19 in Chinese Uigur and Han populations.
Niu CY; Luo JY; Hao ZM
Chin J Dig Dis; 2004; 5(2):76-80. PubMed ID: 15612662
[TBL] [Abstract][Full Text] [Related]
3. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
[TBL] [Abstract][Full Text] [Related]
4. [Cytochrome P450 2C19 gene polymorphism in 104 Chinese Zang volunteers].
Ding HW; Dong WZ; Jiang ZG; Ma X
Yi Chuan; 2004 Mar; 26(2):151-4. PubMed ID: 15639978
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects.
Katsuki H; Nakamura C; Arimori K; Fujiyama S; Nakano M
Eur J Clin Pharmacol; 1997; 52(5):391-6. PubMed ID: 9272410
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 polymorphism as a predictor of personalized therapy in South Indian population.
Siddapuram SP; Banerjee R; Tandan M; Prathap N; Mitnal S; Duvvuru NR
J Assoc Physicians India; 2011 Aug; 59():490-3. PubMed ID: 21887904
[TBL] [Abstract][Full Text] [Related]
7. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
[TBL] [Abstract][Full Text] [Related]
8. [Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations].
Zhang S; Dong Z; Tang L; Zhou Q; Wu Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):52-4. PubMed ID: 11836688
[TBL] [Abstract][Full Text] [Related]
9. Cyp2c19 genotype and omeprazole hydroxylation phenotype in Chinese Li population.
Wang JH; Li PQ; Fu QY; Li QX; Cai WW
Clin Exp Pharmacol Physiol; 2007; 34(5-6):421-4. PubMed ID: 17439410
[TBL] [Abstract][Full Text] [Related]
10. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.
Yin OQ; Wing YK; Cheung Y; Wang ZJ; Lam SL; Chiu HF; Chow MS
J Clin Psychopharmacol; 2006 Aug; 26(4):367-72. PubMed ID: 16855453
[TBL] [Abstract][Full Text] [Related]
11. Misclassification of allele CYP2C19*10 as CY2C19*2 by a commonly used PCR-RFLP procedure.
Rasmussen H; Werge T
Genet Test; 2008 Mar; 12(1):57-8. PubMed ID: 18373404
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.
Hu YR; Qiao HL; Kan QC
Acta Pharmacol Sin; 2004 Aug; 25(8):986-90. PubMed ID: 15301728
[TBL] [Abstract][Full Text] [Related]
13. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population.
Kubota T; Chiba K; Ishizaki T
Clin Pharmacol Ther; 1996 Dec; 60(6):661-6. PubMed ID: 8988068
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
[TBL] [Abstract][Full Text] [Related]
15. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
Brøsen K; de Morais SM; Meyer UA; Goldstein JA
Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
[TBL] [Abstract][Full Text] [Related]
16. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
Hu YM; Mei Q; Xu XH; Hu XP; Hu NZ; Xu JM
World J Gastroenterol; 2006 Aug; 12(29):4750-3. PubMed ID: 16937451
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
Zand N; Tajik N; Moghaddam AS; Milanian I
Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
[TBL] [Abstract][Full Text] [Related]
19. Allele and genotype frequency of CYP2C19 in a Tamilian population.
Adithan C; Gerard N; Vasu S; Rosemary J; Shashindran CH; Krishnamoorthy R
Br J Clin Pharmacol; 2003 Sep; 56(3):331-3. PubMed ID: 12919183
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects.
Ieiri I; Kubota T; Urae A; Kimura M; Wada Y; Mamiya K; Yoshioka S; Irie S; Amamoto T; Nakamura K; Nakano S; Higuchi S
Clin Pharmacol Ther; 1996 Jun; 59(6):647-53. PubMed ID: 8681489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
